Pliant Therapeutics (PLRX) Competitors

$1.21 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.23 +0.02 (+1.98%)

As of 05/22/2026 06:25 PM Eastern

PLRX vs. AKBA, ACIU, PRLD, NLTX, and ALXO

Should you buy Pliant Therapeutics stock or one of its competitors? MarketBeat compares Pliant Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pliant Therapeutics include Akebia Therapeutics (AKBA), AC Immune (ACIU), Prelude Therapeutics (PRLD), Neoleukin Therapeutics (NLTX), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry.

How does Pliant Therapeutics compare to Akebia Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 8.0% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pliant Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 147.93%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 357.52%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pliant Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Pliant Therapeutics' return on equity of -58.11% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Akebia Therapeutics has higher revenue and earnings than Pliant Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	47.42	-$149.34M	-$1.84	N/A
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A

In the previous week, Pliant Therapeutics had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 1 mentions for Akebia Therapeutics. Pliant Therapeutics' average media sentiment score of 0.47 beat Akebia Therapeutics' score of 0.37 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pliant Therapeutics beats Akebia Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to AC Immune?

Pliant Therapeutics (NASDAQ:PLRX) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 147.93%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 165.02%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Pliant Therapeutics and Pliant Therapeutics both had 3 articles in the media. AC Immune's average media sentiment score of 0.92 beat Pliant Therapeutics' score of 0.47 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pliant Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

AC Immune has higher revenue and earnings than Pliant Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	47.42	-$149.34M	-$1.84	N/A
AC Immune	$4.31M	66.82	-$85.03M	-$0.82	N/A

Pliant Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Pliant Therapeutics' return on equity of -58.11% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
AC Immune	-1,788.02%	-125.26%	-40.85%

Summary

AC Immune beats Pliant Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Pliant Therapeutics had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 0 mentions for Prelude Therapeutics. Pliant Therapeutics' average media sentiment score of 0.47 beat Prelude Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Prelude Therapeutics	Neutral
Pliant Therapeutics	Neutral

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prelude Therapeutics has higher revenue and earnings than Pliant Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	22.16	-$99.50M	-$1.00	N/A
Pliant Therapeutics	$1.58M	47.42	-$149.34M	-$1.84	N/A

Prelude Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Prelude Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 79.55%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 147.93%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Pliant Therapeutics' return on equity of -58.11% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Summary

Pliant Therapeutics beats Prelude Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Neoleukin Therapeutics' return on equity of -37.22% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Neoleukin Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Pliant Therapeutics	$1.58M	47.42	-$149.34M	-$1.84	N/A

In the previous week, Pliant Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 0 mentions for Neoleukin Therapeutics. Pliant Therapeutics' average media sentiment score of 0.47 beat Neoleukin Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Pliant Therapeutics	Neutral

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 147.93%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Pliant Therapeutics beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to ALX Oncology?

Pliant Therapeutics (NASDAQ:PLRX) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Pliant Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

ALX Oncology has lower revenue, but higher earnings than Pliant Therapeutics. ALX Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	47.42	-$149.34M	-$1.84	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, Pliant Therapeutics had 3 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Pliant Therapeutics and 0 mentions for ALX Oncology. Pliant Therapeutics' average media sentiment score of 0.47 beat ALX Oncology's score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
ALX Oncology	Neutral

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 147.93%. ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 132.32%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Comparatively, 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pliant Therapeutics' return on equity of -58.11% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
ALX Oncology	N/A	-124.06%	-85.57%

Summary

Pliant Therapeutics beats ALX Oncology on 8 of the 14 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$74.92M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.66	18.74	21.21	25.65
Price / Sales	47.42	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.45	7.09	10.37	7.14
Net Income	-$149.34M	$24.45M	$3.57B	$335.98M
7 Day Performance	5.22%	6.38%	6.40%	4.15%
1 Month Performance	-2.42%	2.43%	3.53%	2.54%
1 Year Performance	-6.20%	62.98%	34.04%	35.06%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.8125 of 5 stars	$1.21 flat	$3.00 +147.9%	-6.2%	$74.92M	$1.58M	N/A	90	Gap Up
AKBA Akebia Therapeutics	2.4333 of 5 stars	$1.01 -4.7%	$4.67 +362.0%	-64.3%	$284.35M	$236.20M	N/A	430
ACIU AC Immune	2.6417 of 5 stars	$2.77 -0.7%	$7.50 +170.8%	+67.5%	$283.95M	$4.31M	N/A	140
PRLD Prelude Therapeutics	4.0696 of 5 stars	$4.34 -3.1%	$7.67 +76.7%	+381.8%	$282.25M	$12.14M	N/A	120
NLTX Neoleukin Therapeutics	N/A	$29.82 -4.6%	N/A	+60.4%	$280.25M	N/A	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. AKBA, ACIU, PRLD, NLTX, and ALXO

How does Pliant Therapeutics compare to Akebia Therapeutics?

Summary

How does Pliant Therapeutics compare to AC Immune?

Summary

How does Pliant Therapeutics compare to Prelude Therapeutics?

Summary

How does Pliant Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. AKBA, ACIU, PRLD, NLTX, and ALXO

How does Pliant Therapeutics compare to Akebia Therapeutics?

Do institutionals and insiders have more ownership in PLRX or AKBA?

Do analysts rate PLRX or AKBA?

Which has more volatility & risk, PLRX or AKBA?

Is PLRX or AKBA more profitable?

Which has stronger valuation and earnings, PLRX or AKBA?

Does the media favor PLRX or AKBA?

Summary

How does Pliant Therapeutics compare to AC Immune?

Do analysts rate PLRX or ACIU?

Does the media favor PLRX or ACIU?

Do insiders and institutionals have more ownership in PLRX or ACIU?

Which has more risk and volatility, PLRX or ACIU?

Which has better valuation & earnings, PLRX or ACIU?

Is PLRX or ACIU more profitable?

Summary

How does Pliant Therapeutics compare to Prelude Therapeutics?

Does the media prefer PRLD or PLRX?

Do institutionals & insiders hold more shares of PRLD or PLRX?

Which has stronger earnings and valuation, PRLD or PLRX?

Which has more volatility and risk, PRLD or PLRX?

Do analysts rate PRLD or PLRX?

Is PRLD or PLRX more profitable?

Summary

How does Pliant Therapeutics compare to Neoleukin Therapeutics?

Is NLTX or PLRX more profitable?

Which has better earnings & valuation, NLTX or PLRX?

Does the media prefer NLTX or PLRX?

Do analysts rate NLTX or PLRX?

Do institutionals and insiders hold more shares of NLTX or PLRX?

Which has more risk & volatility, NLTX or PLRX?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Which has more volatility & risk, PLRX or ALXO?

Which has better valuation and earnings, PLRX or ALXO?

Does the media favor PLRX or ALXO?

Do analysts recommend PLRX or ALXO?

Do institutionals and insiders hold more shares of PLRX or ALXO?

Is PLRX or ALXO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools